Geoffrey Porges Healthcare News

This is selected healthcare news for Geoffrey Porges, which is filed under People. There are 429 news items for this page.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
8/19/2022 Bill Gates And Cathie Wood Have This One Stock In Common, And She Just Bought Some More | Markets Insider
... in the same period last year. It guided to a full-year revenue to $161 million-$181 million, representing 17-31% percent growth. Schrodinger recently appointed Geoffrey Porges as its chief financial officer. Also Read: Alibaba, Other Hong Kong Stocks Show Optimism In Early Trade Even As Analysts Downgrade China Growth ...
Business Insider
8/18/2022 Longtime analyst Geoffrey Porges departs SVB to lead finances at a drug discovery shop – Endpoints News
Geoffrey Porges has ended his two-decade run as a biotech analyst, as the former SVB Securities vice chair began as CFO of Schrödinger on Thursday. The long-running analyst, who previously headed up vaccines marketing at Merck before the turn of the millennium, will lead the financial operations ...
endpts.com
8/18/2022 Schrödinger names longtime biotech analyst Porges its CFO and top dealmaker | BioPharma Dive
Schrödinger on Thursday named Geoffrey Porges its chief financial officer and top dealmaker, putting the high-profile biotechnology analyst in charge of a long list of partnerships that it intends to grow. The New York biotech, known for its drug discovery capabilities, said Porges will oversee its financial operations ...
BioPharma Dive
8/18/2022 Schrödinger Appoints Geoffrey Porges as Chief Financial Officer
NEW YORK--(BUSINESS WIRE)--Aug 18, 2022-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Geoffrey Porges, MBBS., as chief financial officer. Dr. Porges brings to Schrödinger more than 30 years of experience ...
Business Wire
8/18/2022 Schrödinger Appoints Geoffrey Porges as Chief Financial Officer | Business Wire
NEW YORK--( BUSINESS WIRE )-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Geoffrey Porges, MBBS., as chief financial officer. Dr. Porges brings to Schrödinger more than 30 years of experience in executive, advisory ...
Business Wire
8/18/2022 Schrödinger Appoints Geoffrey Porges as Chief Financial Officer
Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Geoffrey Porges, MBBS., as chief financial officer. Dr. Porges brings to Schrödinger more than 30 years of experience in executive, advisory and investment roles within ...
insidertracking.com
8/18/2022 Schrödinger Appoints Geoffrey Porges as Chief Financial Officer | BioSpace
NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Geoffrey Porges, MBBS., as chief financial officer. Dr. Porges brings to Schrödinger more than 30 years of experience in executive, advisory ...
BioSpace
8/18/2022 Schrödinger appoints Geoffrey Porges as CFO
Geoffrey Porges, MBBS, has been named chief financial officer by Schrödinger, Inc., whose physics-based software platform is revolutionising the way treatments and materials are found. More than 30 years of experience in leadership, advisory, and investment roles in the biopharmaceutical sector are brought to Schrödinger by Dr ...
bollyinside.com
8/18/2022 Schrödinger Appoints Geoffrey Porges as Chief Financial Officer
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Geoffrey Porges, MBBS., as chief financial officer. Dr. Porges brings to Schrödinger more than 30 years of experience in executive, advisory ...
acrofan.com
8/18/2022 Schrödinger Appoints Geoffrey Porges as Chief Financial Officer
NEW YORK‚Ai(BUSINESS WIRE)‚Ai Schr√∂dinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Geoffrey Porges, MBBS., as chief financial officer. Dr. Porges brings to Schr√∂dinger more than 30 years of experience in ...
metrolatinousa.com
8/18/2022 2022-08-18 | NDAQ:SDGR | Press Release | Schrodinger Inc.
SDGR 20 hours ago Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Geoffrey Porges, MBBS., as chief financial officer. Dr. Porges brings to Schrödinger more than 30 years of experience in executive, advisory ...
stockhouse.com
9/29/2021 AbbVie pressures Biohaven in migraine prevention with FDA approval for its CGRP blockbuster-to-be Qulipta
... anti-CGRP drug for preventing migraine, setting up a direct battle between two meds that both bear big sales expectations. For Qulipta, SVB Leerink analyst Geoffrey Porges in August projected about $1.2 billion sales in 2030, which he noted was above Wall Street's consensus estimates of $1 billion. Piper ...
FiercePharma
9/28/2021 Merck’s reported $11B Acceleron buy could help it diversify beyond Keytruda, but antitrust hurdles loom: analysts
... experimental drug for pulmonary arterial hypertension (PAH), and that med could spell trouble for the deal with regulators, SVB Leerink analysts Daina Graybosch, Ph.D., and Geoffrey Porges said in separate notes Tuesday. Merck entered the PAH space in 2014 through a licensing deal with Bayer on first-in-class sGC ...
FiercePharma
9/15/2021 U.S. to pay $2.9 billion for an additional 1.4 million doses of Regeneron’s COVID-19 therapy
... deaths all elevated again in the U.S., demand is likely to remain high through year-end, and most likely through the winter," SVB Leerink analyst Geoffrey Porges told investors. He predicts that the treatment will generate $5.4 billion in total sales in 2021. Regeneron's stock has soared 33.5% so far ...
MarketWatch
9/8/2021 GSK, Pfizer and Johnson & Johnson race toward $10B+ RSV vaccine market: analyst
... have suffered high-profile trial failures over the years, vaccines are now advancing through late-stage testing and could launch in 2023, SVB Leerink analyst Geoffrey Porges wrote to clients this week. As companies race to the FDA finish line, a market worth $10.5 billion could take shape over the ...
FiercePharma
9/2/2021 FDA’s new JAK safety restrictions spell trouble for AbbVie’s Rinvoq, but to what extent? | FiercePharma
... later lines, it could mean a $1 billion to $3 billion reduction from AbbVie's $8 billion 2025 sales estimate for the drug, SVB Leerink Geoffrey Porges wrote in a Wednesday note to investors. For his part, Bernstein analyst Ronny Gal reined in his 2030 sales projection for Rinvoq to ...
FiercePharma
8/16/2021 FibroGen’s longtime CFO hands baton to J&J veteran as high-profile roxadustat blowup cues a likely overhaul
... and significantly decrease expenses.‚Au Without the additional cash contribution from roxa in the U.S., FibroGen needs a restructuring to sustain itself, SVB Leerink analyst Geoffrey Porges said in a note to clients after the roxa rebuff. Another drug in development at the biotech, pamrevlumab, is currently in phase 3 ...
FiercePharma
8/11/2021 Surprise, surprise: AstraZeneca and FibroGen's once-hyped anemia drug roxadustat hits an FDA wall
... nondialysis-dependent individuals. The FDA has requested additional clinical studies if FibroGen wants to shoot for an approval ever again. But as SVB Leerink analyst Geoffrey Porges observed in a note last month after the advisory committee vote, AZ's and FibroGen's investors likely won‚Aot be willing to ...
FiercePharma
5/27/2021 Vir Stock Reverses Despite Gaining FDA Nod For GSK-Partnered Covid Drug | Investor’s Business Daily
... at risk of worsening. The companies designed the treatment to withstand existing variants. For GSK, the authorization likely won't be financially material, SVB Leerink analyst Geoffrey Porges said in a report to clients. But this move could generate a "large cash windfall" for Vir. "For Vir, this is a considerable ...
investors.com
5/11/2021 FibroGen Inc. (FGEN) Q1 2021 Earnings Call Transcript
... Ai Stifel Analyst Michael Yee Jefferies Analyst Edwin Zhang H.C. Wainwright Analyst Jason Gerberry Bank of America Analyst Geoffrey Porges SVB Leerink Analyst Brendan Smith Cowen and Company Analyst Difei Yang Mizuho Securities Analyst Lisa Yang ...
alphastreet.com
5/6/2021 Regeneron Pharmaceuticals Inc. (REGN) Q1 2021 Earnings Call Transcript
... Finance and Chief Financial Officer Terence Flynn Goldman Sachs Analyst Chris Raymond Piper Sandler Analyst Cory Kasimov JPMorgan Analyst Geoffrey Porges SVB Leerink Analyst Yatin Suneja Guggenheim Partners Analyst Alex Keller Bank of America Analyst Robyn Karnauskas ...
alphastreet.com
4/28/2021 GlaxoSmithKline plc. (GSK) Q1 2021 Earnings Call Transcript
... Berenberg Analyst Steve Scala Cowen Analyst Andrew Baum Citigroup Analyst Graham Parry Bank of America Merrill Lynch Analyst Geoffrey Porges SVB Leerink Analyst Peter Welford Jefferies Analyst Operator Good afternoon, ladies and gentlemen. And welcome to the Analyst Call ...
alphastreet.com
4/28/2021 Clamping Down On Drug Prices Stifles Innovation, Influential Analyst Says | Kaiser Health News
... Large pharma consolidation can hurt R&D and lead to higher drug prices, Democratic commissioners have said. But those concerns are unfounded, SVB Leerink analyst Geoffrey Porges countered in a recent note to clients. (Liu, 4/26) NJ.com: Cutting Prescription Drug Prices Should Be Next Biden Priority, Powerful N.J. Dem Says ...
Kaiser Health News
4/27/2021 Pharma Industry M&a Scrutiny in Sen. Amy Klobuchar’s Book
... have been contested as attempts to dominate a market . This increased scrutiny and other "regulatory activism" led one of Wall Street's top analysts, SVB Leerink's Geoffrey Porges, to downgrade biopharma stocks last month. Now, one of Congress' leading monopoly-busters and a recent front-runner for attorney general , Sen. Amy ...
Business Insider
4/16/2021 How mRNA vaccines like Moderna’s and Pfizer’s are propelling us into the ‚Äònew golden age‚Äô of vaccinology | Fortune
... the vaccine business, and how an early-mover advantage can lead to a dominant long-term market position for a vaccine manufacturer,‚Au says analyst Geoffrey Porges of SVB Leerink. The prospects In the search for effective COVID-19 vaccines, developers around the world tried a wide spread of vaccine ...
Fortune